A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children with Primary Immunodeficiency Diseases.
Clinical Trial Grant
Administered By
Pediatrics, Allergy and Immunology
Awarded By
ProMetic Life Sciences Inc.
Start Date
January 1, 2017
End Date
January 31, 2020
Administered By
Pediatrics, Allergy and Immunology
Awarded By
ProMetic Life Sciences Inc.
Start Date
January 1, 2017
End Date
January 31, 2020